SCHEMBL7141646

SCHEMBL7141646

CN(CCCCC#Cc1ccc2cncnc2c1)N(C=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.36
GBA1 P04062 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylamine SCHEMBL7141650 0.72 ADORA3 (0.42) GBA1
SCHEMBL6776176 0.71 SRC (0.37) EGFR
SCHEMBL7141657 0.70 HDAC4 (0.34) EGFRGBA1
SCHEMBL6775465 0.66 KDM4E (0.30)
SCHEMBL2010330 0.61 EGFR (0.55) EGFR
SCHEMBL738516 0.58 EGFR (0.55) EGFR
SCHEMBL27557205 0.58 EGFR (0.55) EGFR
SCHEMBL5077890 0.58 EGFR (0.51) EGFR
SCHEMBL7682831 0.56 FFAR1 (0.41)
SCHEMBL7959593 0.56 EGFR (0.51) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1272185-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2003-01-08 EP disclosed
WO-2001066099-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2001-09-13 WO disclosed